bluebird bio (NASDAQ:BLUE) Trading Up 7.4%

bluebird bio, Inc. (NASDAQ:BLUEGet Rating) was up 7.4% during trading on Wednesday . The company traded as high as $8.17 and last traded at $7.07. Approximately 684,447 shares changed hands during trading, a decline of 89% from the average daily volume of 6,303,871 shares. The stock had previously closed at $6.58.

Analyst Ratings Changes

A number of research analysts have recently commented on BLUE shares. Wedbush dropped their price target on bluebird bio from $10.00 to $8.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 10th. Morgan Stanley decreased their price objective on bluebird bio to $3.00 and set an “underweight” rating on the stock in a research note on Tuesday, May 17th. Raymond James upgraded bluebird bio from a “market perform” rating to an “outperform” rating and set a $8.00 target price on the stock in a research note on Tuesday, August 2nd. Finally, Barclays upgraded bluebird bio from an “underweight” rating to an “equal weight” rating and upped their target price for the stock from $3.00 to $5.00 in a research note on Friday, August 5th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, bluebird bio presently has a consensus rating of “Hold” and an average target price of $10.50.

bluebird bio Stock Performance

The firm has a market capitalization of $546.01 million, a PE ratio of -0.87 and a beta of 1.29. The stock’s 50-day simple moving average is $4.66 and its 200-day simple moving average is $4.72.

bluebird bio (NASDAQ:BLUEGet Rating) last announced its earnings results on Thursday, August 4th. The biotechnology company reported ($1.29) EPS for the quarter, beating analysts’ consensus estimates of ($1.31) by $0.02. bluebird bio had a negative net margin of 2,141.34% and a negative return on equity of 130.19%. The firm had revenue of $1.52 million for the quarter, compared to analysts’ expectations of $6.47 million. As a group, analysts predict that bluebird bio, Inc. will post -4.81 earnings per share for the current fiscal year.

Insider Buying and Selling at bluebird bio

In other bluebird bio news, CEO Andrew Obenshain sold 21,805 shares of the company’s stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $4.39, for a total transaction of $95,723.95. Following the transaction, the chief executive officer now owns 247,131 shares in the company, valued at approximately $1,084,905.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Jason Cole sold 7,448 shares of bluebird bio stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $4.39, for a total transaction of $32,696.72. Following the transaction, the insider now owns 203,740 shares in the company, valued at approximately $894,418.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Andrew Obenshain sold 21,805 shares of the business’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $4.39, for a total transaction of $95,723.95. Following the completion of the sale, the chief executive officer now owns 247,131 shares in the company, valued at approximately $1,084,905.09. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,364 shares of company stock worth $146,664. Company insiders own 2.90% of the company’s stock.

Institutional Trading of bluebird bio

Hedge funds have recently bought and sold shares of the stock. Amalgamated Bank bought a new stake in shares of bluebird bio in the 1st quarter worth about $39,000. PEAK6 Investments LLC bought a new stake in shares of bluebird bio in the 2nd quarter worth about $41,000. US Bancorp DE grew its holdings in bluebird bio by 82.9% during the 1st quarter. US Bancorp DE now owns 8,486 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 3,847 shares during the last quarter. Keybank National Association OH bought a new position in bluebird bio during the 2nd quarter valued at about $42,000. Finally, Laurion Capital Management LP bought a new position in bluebird bio during the 2nd quarter valued at about $42,000. Hedge funds and other institutional investors own 96.38% of the company’s stock.

bluebird bio Company Profile

(Get Rating)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.

See Also

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.